Solutions: Pharmaceutical
HRDD-aligned due diligence for responsible sourcing across pharmaceutical supply chains.
The ProblemMedicines exist to protect and improve lives. But the supply chains that produce them - from raw chemical extraction through API manufacturing, packaging, and distribution - carry serious risks : forced labour in production facilities, hazardous chemical exposure, environmental contamination , corruption in procurement, and ethical concerns around clinical trials.
-
We support businesses across the pharmaceutical value chain to assess risks, understand impacts, and evaluate the maturity of their responsible sourcing practices. Our approach combines proprietary data analytics with systematic verification methodologies, delivering thorough yet pragmatic due diligence tailored to your business needs and regulatory requirements.
Support pharmaceutical companies to assess risks, impacts, and the maturity of responsible business practices across API sourcing, excipient procurement, and manufacturing operations
Deliver pragmatic, ESG-focused due diligence informed by extensive on-the-ground experience across pharmaceutical manufacturing, API production, and medical device supply chains
Provide clear, tailored reporting aligned with business and stakeholder needs
Help pharmaceutical manufacturers identify and mitigate human rights, social, and environmental risks linked to suppliers and sub-tier API producers
Conduct supplier due diligence for CMOs, API manufacturers, excipient suppliers, and packaging producers against industry standards and responsible sourcing frameworks
Support investors and financiers in assessing ESG and human rights risks in pharmaceutical transactions and M&A.
Enable pharmaceutical companies to understand and manage ESG risks arising from procurement activities across complex, multi-tier supply chains
-
We are regularly asked to produce insight reports and data-driven research and analysis for a wide range of clients.
Our expert team of responsible sourcing specialists and data analysts have access to world-leading data insights which can help teams with:
Informed decision making on complex topics covering API production regions, manufacturing hubs, and raw material sourcing areas globally
Legislation gap analysis to support internal audit programs and help your audit team understand the most likely areas of non-conformance with regulations like the German Supply Chain Act, CSDDD, and emerging pharmaceutical supply chain transparency requirements
Develop risk assessments and opportunities for global pharmaceutical companies' responsible sourcing programmes
Develop bespoke supplier reports for your teams to understand potential risks, opportunities and gap assessments against your expected standards and industry codes of conduct
Chemical and raw material specific risk assessments for critical pharmaceutical inputs
-
Benchmarking and Maturity Assessment – We benchmark management systems and operating practices against compliance frameworks and pharmaceutical industry standards. Our deep data insights platform assesses current performance and identifies priority improvements across API sourcing, manufacturing, and quality systems
Management System Design and Implementation – We design and implement management systems for responsible business conduct and supply chain due diligence. This includes policies, procedures, risk assessment processes, supplier qualification protocols, API traceability systems, environmental management for pharmaceutical waste, and reporting to meet regulatory requirements like the German Supply Chain Act and CSDDD
Audit Preparation and Corrective Action Support – We prepare pharmaceutical manufacturers, CMOs, and API producers for audits against industry standards, assurance frameworks, and regulatory requirements. Our support includes gap assessments, documentation development, staff training, and implementing corrective actions from previous audits
-
Supplier Due Diligence Assessments - We deliver independent due diligence assessments of API manufacturers, excipient suppliers, CMOs, packaging suppliers, and raw material producers against HRDD requirements and industry standards. Our assessments include:
Red flag evaluations against serious abuses including forced labour, unsafe working conditions, and environmental contamination
Sub-national risk classification using our proprietary risk assessment framework—revealing facility-level and district-level risk variation that national classifications miss
Supply chain traceability verification and documentation review across multi-tier API and excipient supply chains
Stakeholder impact assessments including worker voice and community engagement
Environmental risk assessments specific to pharmaceutical manufacturing (wastewater, chemical handling, pharmaceutical waste)
Clear gap analysis and corrective action recommendations
-
Salient ESG issue identification specific to pharmaceutical product categories and API portfolios
Comprehensive human rights and environmental risk profiling for sourcing regions and manufacturing locations
API supply chain concentration and diversification risk analysis
Environmental impact assessments for pharmaceutical manufacturing and waste management
Water usage and wastewater treatment risk assessments
Chemical handling and occupational health risk profiling
Historical legacy issues and reputational exposure assessments
Community relations vulnerabilities around manufacturing sites
Labour rights conditions including contract workers, laboratory staff, and manufacturing personnel
Clinical trial ethics and patient safety considerations in global research operations
Risk integration into sourcing decisions and supplier qualification processes
Anti-corruption and bribery risk assessments across distribution and procurement
-
Crafting and implementing a robust human rights strategy is complex, encompassing sustainable development, worker safety, and mitigation of negative impacts. It must also consider environmental impacts, such as pharmaceutical contamination of water systems, chemical pollution, hazardous waste management, and occupational health risks.
A Human Rights Impact Assessment (HRIA) can help a pharmaceutical company assess and address the legal requirements relating to its existing or potential human rights impacts and meet its responsibility to address all human rights across its extended supply chains—from raw material extraction through API production, manufacturing, and distribution to healthcare delivery.
Aseri can help you determine if the specific human rights issues that affect your company are covered by other impact assessments or due diligence processes, and whether they require a separate HRIA – ensuring compliance with sustainable business regulations and maintaining the highest standards of patient safety and ethical conduct.
-
Awareness raising, procurement and sourcing team training to better understand risks, internal audit capacity training as well as full audit training. Our auditors are accredited to the highest standards including ISO 14001, 45001, APSCA CSCA and have conducted thousands of audits globally. We can:
Train your team in the environmental, social and governance issues present in pharmaceutical supply chains, and how to identify and mitigate risk across API sourcing, manufacturing, and distribution
Help your team to implement any improvement actions needed to close the gaps identified during audits and assessments
Provide the tools to improve operations in line with international and recognised standards and regulations, developing long-term internal capacity
Build supplier capability to meet pharmaceutical industry standards and improve working conditions throughout manufacturing supply chains
Deliver specialised training on pharmaceutical-specific risks including chemical safety, environmental compliance, API traceability, and anti-corruption measures
We help you to understand issues across your extended supply chains, and put the right systems in place to address them.
The SolutionWe work with pharmaceutical manufacturers, API producers, contract manufacturing organisations (CMOs), medical device companies, and healthcare distributors to implement HRDD-aligned due diligence systems that meet regulatory requirements while strengthening operational performance and patient safety.
Our approach combines proprietary data intelligence with deep pharmaceutical sector expertise to deliver practical, effective solutions.
Why our approach works
We use a proprietary data platform that assesses risk at facility and district level, not just nationally. That granularity matters enormously in pharmaceutical sourcing, where a single API producer in a high-risk area can represent significant exposure across an entire product portfolio.
Our team has conducted thousands of audits globally, accredited to ISO 14001, ISO 45001, and APSCA CSCA standards, and we bring specific expertise in the environmental and occupational health risks that are particular to pharmaceutical manufacturing — wastewater management, chemical handling, and pharmaceutical waste contamination.
Built for a highly regulated industry
We understand that pharmaceutical companies operate under intense regulatory scrutiny We help businesses meet legislation including the EU's CSDDD and the German Supply Chain Act, while designing systems that integrate with existing supplier qualification and quality management processes, rather than duplicating them.
The ethical case
Patients trust that the medicines they take were made responsibly. That trust extends all the way down the supply chain; to the workers in API factories, to the communities near manufacturing sites bearing the cost of chemical pollution, and to the individuals involved in global clinical research. Genuine assurance means accounting for all of them, not just ticking a compliance box.